Selective MMP13 inhibitors

Medicinal Research Reviews

Volumn 31, Issue 6, 2011, Pages 863-894

  Li, Jie Jack ^a   Johnson, Adam R ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b GENENTECH INC   (United States)

Author keywords

Collagen; Inflammation; Inhibitor; MMP13; Osteroarthritis

Indexed keywords

4 [[[4 (4 CHLOROPHENOXY)PHENYL]SULFONYL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOHYDROXAMIC ACID; ACETOHYDROXAMIC ACID; ALPHA AMINO SULFONYL HYDROXAMIC ACID; BATIMASTAT; CARBOXYLIC ACID; CGS 27023A; CL 82198; COLLAGENASE 3; DICARBOXAMIDE; DOXYCYCLINE; HYDROXAMIC ACID DERIVATIVE; ILOMASTAT; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; N (BENZOFURANCARBONYLAMINOBIPHENYLSULFONYL)VALINE; PRINOMASTAT; PYRIDO[3,4 D]PYRIMIDIN 4 ONE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; UNCLASSIFIED DRUG; WAY 152177; WAY 170523; ZINC ION;

ALLOSTERISM; ANTERIOR CRUCIATE LIGAMENT; ARTHRITIS; BINDING AFFINITY; BIOAVAILABILITY; BIOCHEMISTRY; BREAST CANCER; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL DIFFERENTIATION; CRYSTAL STRUCTURE; DISEASE COURSE; DISEASE MODEL; DISSOCIATION; DOWN REGULATION; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TOLERABILITY; EARLY TERMINATION OF CLINICAL TRIAL; ENZYME ACTIVATION; EXPERIMENTAL ANIMAL; EXPERIMENTAL MONKEY; EXPERIMENTAL RABBIT; EXPERIMENTAL RAT; GENOTOXICITY; HUMAN; HYDROPHOBICITY; HYPERBILIRUBINEMIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR INTERACTION; MUSCULOSKELETAL DISEASE; NEOPLASM; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; PATENT; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; TUMOR VOLUME; UPREGULATION; X RAY CRYSTALLOGRAPHY;

ALLOSTERIC SITE; ANIMALS; CARTILAGE; COLLAGEN; DRUG DESIGN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INFLAMMATION; KINETICS; MATRIX METALLOPROTEINASE 13; MICE; MICE, KNOCKOUT; OSTEOARTHRITIS; PROTEASE INHIBITORS; RATS;

EID: 80053959979     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20204     Document Type: Review

References (93)

1. Freije JMP, Díez-Itza I, Balbín M, Sánchez LM, Blasco R, Tolivia J, López-Otín C. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinoma. J Biol Chem 1994;269:16766-16773.
2. Welgus HG, Kobayashi DK, Jeffrey JJ. The collagen substrate specificity of rat uterus collagenase. J Biol Chem 1983;258:14162-14165.
3. Knäuper V, López-Otín C, Smith B, Knight G, Murphy G. Biochemical characterization of human collagenase-3. J Biol Chem 1996;271:1544-1550.
4. Welgus HG, Grant GA, Sacchettini JC, Roswit WT, Jeffrey JJ. The gelatinolytic activity of rat uterus collagenase. J Biol Chem 1985;260:13601-13606.
5. Klatt AR, Paul-Klausch B, Klinger G, Kühn G, Renno JH, Bannerjee M, Malchau G, Wielckens K. A critical role for collagen II in cartilage matrix degradation: Collagen II induces pro-inflammatory cytokines and MMPs in primary human chondrocytes. J Orthop Res 2009;27:65-70.
6. Fichter M, Körner U, Schömburg J, Jennings L, Cole AA, Mollenhauer J. Collagen degradation products modulate matrix metalloproteinase expression in cultured articular chondrocytes. J Orthop Res 2006;24:63-70.
7. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Posner PJ, Geoghegan KF, Hambor JE. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 1996;97:761-768.
8. Wernicke D, Seyfert C, Hinzmann B, Gromnica-Ihle E. Cloning of collagenase-3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis. J Rheumatol 1996;23:590-595.
9. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, Mitchell P, Hambor J, Diekmann O, Tschesche H, Chen J, Van Wart H, Poole AR. Enhanced cleavage of type II collagen by collagenases in osteoarthritis articular cartilage. J Clin Invest 1997;99:1534-1545.
10. Billinghurst RC, Wu W, Ionescu M, Reiner A, Dahlberg L, Chen J, Van Wart H, Poole AR. Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase. Arthritis Rheum 2000;43:664-672.
11. Neuhold LA, Killar L, Zhao W, Sung M-LA, Warner L, Kulik J, Turner J, Wu W, Billinghurst C, Meijers T, Poole AR, Babij P, DeGennaro LJ. Postnatal expression of constitutively active human collagenase-3 (MMP13) induces osteoarthritis in mice. J Clin Invest 2001;107:35-44.
12. Johansson N, Saarialho-Kere U, Airola K, Herva R, Nissinen L, Westermarck J, Vuorio E, Heino J, Kähäri V-M. Collagenase-3 (MMP-13) is expressed by hypertrophic chondrocytes, periosteal cells, and osteoblasts during human fetal bone development. Dev Dyn 1997;208:387-397.
13. Stickens D, Behonick DJ, Ortega N, Heyer B, Hartenstein B, Yu Y, Fosang AJ, Schorpp-Kistner M, Angel P, Werb Z. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development 2004;131:5883-5895.
14. Inada M, Wang Y, Byrne MH, Rahman MU, Miyaura C, López-Otín C, Krane SM. Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. Proc Natl Acad Sci USA 2004;101:17192-17197.
15. Karsdal MA, Madsen SH, Christiansen S, Henriksen K, Fosang AJ, Sondergaard BC. Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther 2008;10:R63.
16. Little CB, Barai A, Burkhardt D, Smith SM, Fosang AJ, Werb Z, Shah M, Thompson EW. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum 2009;60:3723-3733.
17. Johansson N, Airola K, Grenman R, Kariniemi AL, Saarialho-Kere U, Kähäri V-M. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 1997;151:499-508.
18. Airola K, Johansson N, Kariniemi AL, Kähäri V-M, Saarialho-Kere UK. Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J Invest Dermatol 1997;109:225-231.
19. Etoh T, Inoue H, Yoshikawa Y, Barnard GF, Kitano S, Mori M. Increased expression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressiveness. Gut 2000;47:50-56.
20. Leeman MF, McKay JA, Murray GI. Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol 2002;55:758-762.
21. Luukkaa M, Vihinen P, Kronqvist P, Vahlberg T, Pyrhönen S, Kähäri V-M, Grénman R. Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer. Head Neck 2006;28:225-234.
22. Luukkaa H, Klemi P, Hirsimäki P, Vahlberg T, Kivisaari A, Kähäri V-M, Grénman R. Matrix metalloproteinase (MMP)-1, -9, and -13 as prognostic factors in salivary gland cancer. Acta Otolaryngol 2008;128:482-490.
23. Zhang B, Cao X, Liu Y, Cao W, Zhang F, Zhang S, Li H, Ning L, Fu L, Niu Y, Niu R, Sun B, Hao X. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer 2008;8:83-92.
24. Chang H-J, Yang M-J, Yang Y-H, Hou M-F, Hsueh E-J, Lin S-R. MMP13 is potentially a new tumor marker for breast cancer diagnosis. Oncol Rep 2009;22:1119-1127.
25. Hoekstra R, Eskens FALM, Verweij J. Matrix metalloproteinase inhibitors: Current developments and future perspectives. Oncologist 2001;6:415-427.
26. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 2004;9:63-79.
27. Peterson JT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res 2006;69:677-687.
28. Reiter LA, Robinson RP, McClure KF, Jones CS, Reese MR, Mitchell PG, Otterness IG, Bliven ML, Liras J, Cortina SR, Donahue KM, Eskra JD, Griffiths RJ, Lame ME, Lopez-Anaya A, Martinelli GJ, McGahee SM, Yocum SA, Lopresti-Morrow LL, Tobiassen LM, Vaughn-Bowser ML. Pyran-containing sulfonamide hydroxamic acids: Potent MMP inhibitors that spare MMP1. Bioorg Med Chem Lett 2004;14:3389-3395.
29. Freeman-Cook KD, Reiter LA, Noe MC, Antipas AS, Danley DE, Datta K, Downs JT, Eisenbeis S, Eskra JD, Garmene DJ, Greer EM, Griffiths RJ, Guzman R, Hardink JR, Janat F, Jones CS, Martinelli GJ, Mitchell PG, Laird ER, Liras JL, Lopresti-Morrow LL, Pandit J, Reilly UD, Robertson D, Vaughn-Bowser ML, Wolf-Gouviea LA, Yocum SA. Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP13. Bioorg Med Chem Lett 2007;17:6529-6534.
30. Johnson AR, Pavlovsky AG, Ortwine DF, Prior F, Man CF, Bornemeier DA, Banotai CA, Mueller WT, McConnell P, Yan C, Baragi V, Lesch C, Roark WH, Wilson M, Datta K, Guzman R, Han HK, Dyer RD. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 2007;282:27781-27791.
31. Dyer RD, Hupe DJ, Johnson AR. Method for identifying metalloenzyme inhibitors. US Patent Application 0129672 (2003 Warner-Lambert).
32. Gooljarsingh LT, Lakdawala A, Coppo F, Luo L, Fields GB, Tummino PJ, Gontarek RR. Characterization of an exosite binding inhibitor of matrix metalloproteinase 13. Protein Sci 2008;17:66-71.
33. Lauer-Fields JL, Minond D, Chase PS, Baillargeon PE, Saldanha SA, Stawikowska R, Hodder P, Fields GB. High throughput screening of potentially selective MMP13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem 2009;17:990-1005.
34. Engel CK, Pirard B, Schimanski S, Kirsch R, Habermann J, Klinger O, Schlotte V, Weithmann KU, Wendt KU. Structural basis for the highly selective inhibition of MMP13. Chem Biol 2005;12:181-189.
35. Murphy G, Nagase H. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: Destruction or repair? Nat Clin Prac Rheumatol 2008;4:128-135.
36. Jacobsen JA, Major Jourden JL, Miller MT, Cohen SM. To bind zinc or not to bind zinc: An examination of innovative approaches to improved matrix metalloproteinase inhibition. Biochim Biophys Acta 2009. DOI: 10.1016/j.bbamcr.2009.08.006.
37. Yiotakis A, Dive V. Third-generation MMP inhibitors: Recent advances in the development of highly selective inhibitors. In: Edwards D, Høyer-Hansen G, Blasi F, Sloane BF (Eds). Springer New York. The cancer degradome: Proteases and cancer biology. 2008. pp 811-825.
38. Breuer E, Frant J, Reich R. Recent non-hydroxamate matrix metalloproteinase inhibitors. Expert Opin Ther Pat 2005;15:253-269.
39. Hajduk PJ, Sheppard G, Nettesheim DG, Olejniczak ET, Shuker SB, Meadows RP, Steinmann DH, Carrera GM, Jr, Marcotte PA, Severin J, Walter K, Smith H, Gubbins E, Simmer R, Holzman TF, Morgan DW, Davidsen SK, Summers JB, Fesik SW. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J Am Chem Soc 1997;119:5818-5827.
40. Jencks WP. On the attribution and additivity of binding energies. Proc Natl Acad Sci USA 1981;78:4046-4050.
41. Olejniczak ET, Hajduk PJ, Marcotte PA, Nettesheim DG, Meadows RP, Edalji R, Holzman TF, Fesik SW. Stromelysin inhibitors designed from weakly binding fragments: Effects of linking and cooperativity. J Am Chem Soc 1997;119:5828-5832.
42. Johnson AR. Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors. US Patent Application 0063673 (2004 Warner-Lambert).
43. Hellio Le Graverand M-P, Brandt KD, Mazzuca SA, Katz BP, Buck R, Lane KA, Pickering E, Nemirovskiy OV, Sunyer T, Welsch DJ. Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis. Osteoarthr Cartilage 2006;14:1189-1195.
44. Janusz MJ, Hookfin EB, Heitmeyer SA, Woessner JF, Freemont AJ, Hoyland JA, Brown KK, Hsieh LC, Almstead NG, De B, Natchus MG, Pikul S, Taiwo YO. Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthr Cartilage 2001;9:751-760.
45. Barve RA, Minnerly JC, Weiss DJ, Meyer DM, Aguiar DJ, Sullivan PM, Weinrich SL, Head RD. Transcriptional profiling and pathway analysis of monosodium iodoacetate-induced experimental osteoarthritis in rats: Relevance to human disease. Osteoarthr Cartilage 2007;15:1190-1198.
46. Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB. Synthesis and structure-activity relationships of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J Med Chem 2003;46:2376-2396.
47. Li JJ, Nahra J, Johnson AR, Bunker A, O'Brien P, Yue WS, Ortwine DF, Man CF, Baragi V, Kilgore K, Dyer RD, Han HK. Quinazolinones and pyrido[3, 4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. J Med Chem 2008;51:835-841.
48. Otterness IG, Brandt KD, Hellio Le Graverand M-P, Mazzuca SA. Urinary TIINE concentrations in a randomized controlled trial of doxycycline in knee osteoarthritis. Implications of the lack of association between TIINE levels and joint space narrowing. Arthritis Rheum 2007;56:3644-3649.
49. Jüngel A, Ospelt C, Lesch M, Thiel M, Sunyer T, Schorr O, Michel BA, Gay RE, Kolling C, Flory C, Gay S, Neidhart M. Effect of the oral application of a highly selective MMP13 inhibitor in three different animal models of rheumatoid arthritis. Ann Rheum Dis 2009. DOI: 10.1136/ard.2008.106021.
50. Renkiewicz R, Qiu L, Lesch C, Sun X, Devalaraja R, Cody T, Kaldjian E, Welgus H, Baragi V. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum 2003;48:1742-1749.
51. Cai H, Agrawal AK, Putt DA, Hashim M, Reddy A, Brodfuehrer J, Surendran N, Lash LH. Assessment of the renal toxicity of novel anti-inflammatory compounds using cynomolgus monkey and human kidney cells. Toxicology 2009;258:56-63.
52. Schnute ME, Carroll JN, Hanau CE, McReynolds MD, Scholten JA, McDonald JJ, Grapperhaus ML, Massa MA, Ruminski PG, Schmidt MA, Strohback JW, Hamper BC, Fletcher TR, Rogers MD, O'Brien PM, Nahra J, Morris MA, Roark WH. Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions. International Patent Application WO 2009/016498 (2009 Pfizer).
53. Datta K, Guzman R, Maier WE, Grzemski FA, Robertson DG. Renal toxicity and hyperbilirubinemia of a novel matrix metalloproteinase (MMP) inhibitor in cynomolgus monkeys. Toxicologist 2006;90:343-344.
54. O'Brien LE, Tang K, Kats ES, Schutz-Geschwender A, Lipschutz JH, Mostov KE. ERK and MMPs sequentially regulate distinct stages of epithelial tubule development. Dev Cell 2004;7:21-32.
55. Hellman NE, Spector J, Robinson J, Zuo X, Saunier S, Antignac C, Tobias JW, Lipschutz JH. Matrix metalloproteinase 13 (MMP13) and tissue inhibitor of matrix metalloproteinase 1 (TIMP1), regulated by the MAPK pathway, are both necessary for Madin-Darby canine kidney tubulogenesis. J Biol Chem 2008;283:4272-4282.
56. Hellio Le Graverand M-P. OA Clinical trials: Current targets and trials for OA. Choosing molecular targets: What have we learned and where are we headed? Osteoarthr Cartilage 2009; 17:1393-1401.
57. Fosang AJ, Little CB. Drug insight: Aggrecanases as therapeutic targets for osteoarthritis. Nat Clin Pract Rheum 2008;4:420-427.
58. Wojtowicz-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Chiodo TA, Hawkins MJ. Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 1998;16:2150-2156.
59. Freskos JN, Mischke BV, DeCrescenzo GA, Heintz R, Getman DP, Howard SC, Kishore NN, McDonald JJ, Munie GE, Rangwala S, Swearingen CA, Voliva C, Welsch DJ. Discovery of a novel series of selective MMP inhibitors: Identification of the γ-sulfone-thiols. Bioorg Med Chem Lett 1999;9:943-948.
60. Freskos JN, McDonald JJ, Mischke BV, Mullins PB, Shieh HS, Stegeman RA, Stevens AM. Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett 1999;9:1757-1760.
61. Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999;878:236-270.
62. Levin JI, et al. WO0044709 WO0044711 WO0044749 (2000 American Cyanamid).
63. Anon. Novel cyclic N-hydroxamic acid inhibitors of TNF-α synthesis and MMP13. Expert Opin Ther Pat 2000;10:1951-1956.
64. Thabet MM, Huizinga TWJ. Drug evaluation: Apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr Opin Invest Dr 2006;7:1014-1019.
65. Levin JI, Chen JM, Laakso LM, Du M, Schmid J, Xu W, Cummons T, Xu J, Jin G, Barone D, Skotnicki JS. Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett 2006;16:1605-1609.
66. Chen JM, Nelson FC, Levin JI, Mobilio D, Moy FJ, Nilakantan R, Zask A, Powers R. Structure-based design of a novel, potent, and selective inhibitor for MMP13 utilizing NMR spectroscopy and computer-aided molecular design. J Am Chem Soc 2000;122:9648-9654.
67. Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G, Cowling R, Skotnicki JS. The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position. Bioorg Med Chem Lett 2001;11:235-238.
68. Levin JI, Gu Y, Nelson FC, Zask A, DiJoseph JF, Sharr MA, Sung A, Jin G, Cowling R, Chanda P, Cosmi S, Hsiao CL, Edris W, Wilhelm J, Killar LM, Skotnicki JS. Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett 2001;11:239-242.
69. Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS. The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P11 groups. Bioorg Med Chem Lett 2001;11:2189-2192.
70. Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS. The discovery of anthranilic acid-based MMP inhibitors. Part 3: Incorporation of basic amines. Bioorg Med Chem Lett 2001;11:2975-2978.
71. Wu J, Rush TS, Hotchandani R, Du X, Geck M, Collins E, Xu ZB, Skotnicki J, Levin JI, Lovering FE. Identification of potent and selective MMP13 inhibitors. Bioorg Med Chem Lett 2005;15:4105-4109.
72. Li J, Rush TS, Li W, DeVincentis D, Du X, Hu Y, Thomason JR, Xiang JS, Skotnicki JS, Tam S, Cunningham KM, Chockalingam PS, Morris ElA, Levin JI. Synthesis and SAR of highly selective MMP13 inhibitors. Bioorg Med Chem Lett 2005;15:4961-4966.
73. Hu Y, Xiang JS, DiGrandi MJ, Du X, Ipek M, Laakso LM, Li J, Li W, Rush TS, Schmid J, Skotnicki JS, Tam S, Thomason JR, Wang Q, Levin JI. Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg Med Chem 2005;13:6629-6644.
74. Robinson RP. WO9907675 (1997 Pfizer).
75. Anon. Arylsulphonamide hydroxamic acids as potent inhibitors of MMP13. Expert Opin Ther Pat 1999;9:1303-1307.
76. Robinson RP, Laird ER, Blake JF, Bordner J, Donahue KM, Lopresti-Morrow LL, Mitchell PG, Reese MR, Reeves LM, Stam EJ, Yocum SA. Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold. J Med Chem 2000;43:2293-2296.
77. Robinson RP, Laird ER, Donahue KM, Lopresti-Morrow LL, Mitchell PG, Reese MR, Reeves LM, Rouch AI, Stam EJ, Yocum SA. Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors. Bioorg Med Chem Lett 2001;11:1211-1213.
78. Letavic MA, Barberia JT, Carty TJ, Hardink JR, Liras J, Lopresti-Morrow LL, Mitchell PG, Noe MC, Reeves LM, Snow SL, Stam EJ, Sweeney FJ, Vaughn ML, Yu CH. Synthesis and biological activity of piperazine-based dual MMP13 and TNF-α converting enzyme inhibitors. Bioorg Med Chem Lett 2003;13:3243-3246.
79. Noe MC, Snow SL, Wolf-Gouveia LA, Mitchell PG, Lopresti-Morrow L, Reeves LM, Yocum SA, Liras JL, Vaughn M. 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP13 and aggrecanase. Bioorg Med Chem Lett 2004;14:4727-4730.
80. Noe MC, Natarajan V, Snow SL, Mitchell PG, Lopresti-Morrow L, Reeves LM, Yocum SA, Carty TJ, Barberia JA, Sweeney FJ, Liras JL, Vaughn M, Hardink JR, Hawkins JM, Tokar C. Discovery of 3, 3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP13. Bioorg Med Chem Lett 2005;15:2808-2811.
81. Noe MC, Natarajan V, Snow SL, Wolf-Gouveia LA, Mitchell PG, Lopresti-Morrow L, Reeves LM, Yocum SA, Otterness I, Bliven MA, Carty TJ, Barberia JT, Sweeney FJ, Liras JL, Vaughn M. Discovery of 3-OH-3-methylpipecolic hydroxamates: Potent orally active inhibitors of aggrecanase and MMP13. Bioorg Med Chem Lett 2005;15:3385-3388.
82. Reiter LA, Robinson RP, McClure KF, Jones CS, Reese MR, Mitchell PG, Otterness IG, Bliven ML, Liras J, Cortina SR, Donahue KM, Eskra JD, Griffiths RJ, Lame ME, Lopez-Anaya A, Martinelli GJ, McGahee SM, Yocum SA, Lopresti-Morrow LL, Tobiassen LM, Vaughn-Bowser ML. Pyran-containing sulfonamide hydroxamic acids: Potent MMP inhibitors that spare MMP1. Bioorg Med Chem Lett 2004;14:3389-3395.
83. Reiter LA, Rizzi JP, Pandit J, Lasut MJ, McGahee SM, Parikh VD, Blake JF, Danley DE, Laird ER, Lopez-Anaya A, Lopresti-Morrow LL, Mansour MN, Martinelli GJ, Mitchell PG, Owens BS, Pauly TA, Reeves LM, Schulte GK, Yocum SA. Inhibition of MMP1 and MMP13 with phosphinic acids that exploit binding in the S2 pocket. Bioorg Med Chem Lett 1999;9:127-132.
84. Reiter LA, Mitchell PG, Martinelli GJ, Lopresti-Morrow LL, Yocum SA, Eskra JD. Phosphinic acid-based MMP13 inhibitors that spare MMP1 and MMP3. Bioorg Med Chem Lett 2003;13:2331-2336.
85. Blagg JA, Noe MC, Wolf-Gouveia LA, Reiter LA, Laird ER, Chang S-PP, Danley DE, Downs JT, Elliott NC, Eskra JD, Griffiths RJ, Hardink JR, Haugeto AI, Jones CS, Liras JL, Lopresti-Morrow LL, Mitchell PG, Pandit J, Robinson RP, Subramanyam C, Vaughn-Bowser ML, Yocum SA. Potent pyrimidinetrione-based inhibitors of MMP13 with enhanced selectivity over MMP14. Bioorg Med Chem Lett 2005;15:1807-1810.
86. Reiter LA, Freeman-Cook KD, Jones CS, Martinelli GJ, Antipas AS, Berliner MA, Datta K, Downs JT, Eskra JD, Forman MD, Greer EM, Guzman R, Hardink JR, Janat F, Keene NF, Laird ER, Liras JL, Lopresti-Morrow LL, Mitchell PG, Pandit J, Robertson D, Sperger D, Vaughn-Bowser ML, Waller DM, Yocum SA. Potent, selective pyrimidinetrione-based inhibitors of MMP13. Bioorg Med Chem Lett 2006;16:5822-5826.
87. Foley LH, Palermo R, Dunten P, Wang P. Novel 5, 5-disubstituted pyrimidine-2, 4, 6-triones as selective MMP inhibitors. Bioorg Med Chem Lett 2001;11:969-972.
88. Barta TE, Becker DP, Bedell LJ, De Crescenzo GA, McDonald JJ, Munie GE, Rao S, Shieh HS, Stegeman R, Stevens AM, Villamil CI. Synthesis and activity of selective MMP inhibitors with an aryl backbone. Bioorg Med Chem Lett 2000;10:2815-2817.
89. Becker DP, Barta TE, Bedell L, DeCrescenzo G, Freskos J, Getman DP, Hockerman SL, Li M, Mehta P, Mischke B, Munie GE, Swearingen C, Villamil CI. α-Amino-β-sulfone hydroxamates as potent MMP13 inhibitors that spare MMP1. Bioorg Med Chem Lett 2001;11:2719-2722.
90. Schudok M, Ruf S, Matter H, Wehner V, Kirsch R, Stahl P. Imino acid derivatives for use as inhibitors of matrix metalloproteinases. International Patent Application WO2004/060883 (2004 Aventis).
91. Klingler O, Kirsch R, Habermann J, Weithmann KU, Engel CK, Pirard B. Pyrimidine-4, 6-dicarboxylic acid diamides for use as selective MMP13 inhibitors. International Patent Application WO2004/060883 (2004 Aventis).
92. Chollet AM, Le Diguarher T, Murray L, Bertrand M, Tucker GC, Sabatini M, Pierre A, Atassi G, Bonnet J, Casara P. General synthesis of α-substituted 3-bis(aryloxy)propionic acid derivatives as specific MMP inhibitors. Bioorg Med Chem Lett 2001;11:295-299.
93. Kim SH, Pudzianowski AT, Leavitt KJ, Barbosa J, McDonnell PA, Metzler WJ, Rankin BM, Liu R, Vaccaro W, Pitts W. Structure-based design of potent and selective inhibitors of collagenase-3 (MMP13). Bioorg Med Chem Lett 2005;15:1101-1106.